FluBlok, a recombinant hemagglutinin influenza vaccine

Abstract  FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg‐based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times...

Descripción completa

Detalles Bibliográficos
Autores principales: Cox, Manon M.J., Patriarca, Peter A., Treanor, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2008
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634115/
https://www.ncbi.nlm.nih.gov/pubmed/19453397
http://dx.doi.org/10.1111/j.1750-2659.2008.00053.x
Descripción
Sumario:Abstract  FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg‐based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg‐protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the ‘Accelerated Approval’ mechanism in the United States.

Ejemplares similares